Trials / Withdrawn
WithdrawnNCT05193279
Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age
A Randomized, Controlled, Dose-finding, Observer-blind, Phase 2/3 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of CpG/Alum-adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccines (SCB-2019 Vaccine) in Children <18 Years of Age
- Status
- Withdrawn
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Clover Biopharmaceuticals AUS Pty · Industry
- Sex
- All
- Age
- 17 Years
- Healthy volunteers
- Accepted
Summary
This is a phase 2/3, randomized, controlled study to assess the reactogenicity, safety and immunogenicity of adjuvanted recombinant SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019), when administered as 2-dose vaccination series in children below 18 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Candidate vaccine, SCB-2019 | a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19 |
Timeline
- Start date
- 2022-10-05
- Primary completion
- 2022-12-15
- Completion
- 2022-12-15
- First posted
- 2022-01-14
- Last updated
- 2023-03-24
Locations
2 sites across 1 country: Colombia
Source: ClinicalTrials.gov record NCT05193279. Inclusion in this directory is not an endorsement.